Month: March 2022

TEJON RANCH, Calif., March 03, 2022 (GLOBE NEWSWIRE) — Tejon Ranch Co., or the Company, (NYSE:TRC), a diversified real estate development and agribusiness company, today announced financial results for the fourth quarter and year-ended December 31, 2021. The Company operates in a variety of land-based business segments, including farming, mineral resources, and ranch operations, as well as a commercial/industrial mixed use master plan known as the Tejon Ranch Commerce Center, that is currently in operation focusing on leasing, commercial/industrial development, multi-family development, and sales. The Company is also in the process of developing three additional mixed use master planned residential developments in southern California. When all four master planned developments are fully built out, Tejon Ranch will be home to 35,278...

Base Dividend of $0.36 Per Share Declared for First Quarter 2022 Board of Directors Declared Supplemental Dividend of $0.17 Per Share EVANSTON, Ill., March 03, 2022 (GLOBE NEWSWIRE) — Fidus Investment Corporation (NASDAQ:FDUS) (“Fidus” or the “Company”), a provider of customized debt and equity financing solutions, primarily to lower middle-market companies based in the United States, today announced its financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 Financial HighlightsTotal investment income of $24.1 million Net investment income of $2.4 million, or $0.10 per share Adjusted net investment income of $12.0 million, or $0.49 per share(1) Net increase in net assets resulting from operations of $50.2 million, or $2.06 per share Invested $101.2 million in debt and equity securities,...

Revenue Increased 36.6% Year over Year; Adjusted Gross Profit Increased 38.4% Year over Year NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) — AdTheorent Holding Company, Inc. (Nasdaq: ADTH) (“AdTheorent” or “the Company”), a programmatic digital advertising leader using advanced machine learning technology and privacy-forward solutions to deliver real-world value for advertisers and marketers, today announced fourth quarter and full-year 2021 financial results. Fourth Quarter 2021 Financial Highlights:Revenue: Revenue increased by $7.9 million in fourth quarter 2021, or 16.8%, to $55.0 million from $47.1 million in fourth quarter 2020, driven by strength across a diverse portfolio of customer verticals.  As measured on a by-channel basis, video revenue, including Connected TV (“CTV”) revenue, increased in excess of 33.3%. Gross...

Multiple data readouts expected in 2022, including updates for all three clinical programsEnds 2021 with cash position of $219.6 million that is expected to fund operations into first quarter of 2024BELTSVILLE, Md., March 03, 2022 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter and full year 2021 financial results and provided a business update.“In 2021, NextCure set the stage for multiple data readouts in 2022. This year, we intend to have important updates on NC318, NC410, and NC762,” said Michael Richman, NextCure’s president and chief executive officer. “Additionally, we expect our year-end cash position of $219.6 million...

Initiated the Phase 1b/2a PACIFIC Study, evaluating LP352 in participants with developmental and epileptic encephalopathies (DEEs) LP352 demonstrated statistically significant reduction of epileptiform event frequency and duration in the scn1lab zebrafish model of Dravet syndrome LP659 IND submission remains on track for second half of 2022 Cash position expected to support operations into 2024 based on current business planSAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) —  Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the full year 2021. “I am very proud of the work our team accomplished over the past year, particularly advancing LP352...

ORANGE, Calif., March 03, 2022 (GLOBE NEWSWIRE) — Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (Nasdaq: ALHC), a tech-enabled Medicare Advantage company, today reported financial results for its fourth quarter and full year ended Dec. 31, 2021. “Our strong fourth-quarter results across critical KPIs punctuated a solid first year for Alignment Healthcare in the public markets. Our success showcased the power of our clinical model and our proprietary AVA® platform to deliver steady growth and an effective medical benefits ratio,” said John Kao, founder and CEO, Alignment Healthcare. “In 2022, we will continue to invest in new markets and the replicability and scalability of our differentiated model,” Kao continued. “We’ve built a solid foundation for continued success, and I am optimistic about our future...

HAUPPAUGE, N.Y., March 03, 2022 (GLOBE NEWSWIRE) — Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter and year ended December 31, 2021. Recent HighlightsAchieved record quarterly total revenue of $20.6 million and product revenue of $17.4 million in the fourth quarter of 2021, representing growth of 101% and 154%, respectively, compared to the prior year period, including:U.S. product revenue of $3.2 million, representing growth of 268% compared to the prior year period Latin America product revenue of $12.0 million, representing growth of 415% compared to the prior year periodAchieved record annual total revenue of $47.8 million and product revenue of $34.7 million for the full...

CAMPBELL, Calif., March 03, 2022 (GLOBE NEWSWIRE) — Arteris, Inc. (Arteris or Arteris IP), a leading provider of network-on-chip (NoC) interconnect and other intellectual property (IP) technology that manages the on-chip communications in system-on-chip (SoC) semiconductor devices, today announced financial results for the fourth quarter and year ended December 31, 2021, and provided estimated first quarter and full year 2022 guidance. “We’re excited to see our momentum continue in the fourth quarter, with our total number of Active Customers increasing from 179 to 192 across a broad base of applications including Machine Learning, Automotive and 5G,” said K. Charles Janac, President and CEO of Arteris IP. “As we look ahead we believe there are a number of tailwinds that help our business including the increase in SoC complexity...

TORONTO, March 03, 2022 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2021. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. Full Year 2021 and Recent Corporate HighlightsOn March 3, 2021, the Company announced the appointment of Cynthia Lavoie Ph.D., MBA, to its Board of Directors. On May 6, 2021, Profound announced a multi-site imaging center agreement for TULSA-PRO®...

PITTSBURGH, March 03, 2022 (GLOBE NEWSWIRE) — Duolingo, Inc. (NASDAQ: DUOL), the world’s leading mobile learning platform, announced results for the fourth quarter and full year ended December 31, 2021 in a shareholder letter that is posted at https://investors.duolingo.com. “In the fourth quarter, our user growth accelerated and we added more net subscribers than ever before, capping off a year in which our revenue grew by 55%,” said Luis von Ahn, Co-Founder and CEO of Duolingo. “I credit this growth and our record-breaking metrics to our focus on making learning fun and effective, and to our new product initiatives that made Duolingo Plus more valuable.” “Looking ahead to 2022, we have exciting plans to make our products even more engaging and valuable for our learners. And we also have plans to continue broadening...